China SXT Pharmaceuticals Inc.

Mar 16, 2020

China SXT Pharmaceuticals, Inc. Announces That It Received a Grant Supported by City Government

Jan 16, 2020

China SXT Pharmaceuticals, Inc. Announced Regulatory Approval of Its DNA Exam Laboratory

Jan 03, 2020

China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency

Sep 11, 2019

China SXT Pharmaceuticals, Inc. Granted to Establish Taizhou Research Center for Advanced TCMP Engineering Techniques

Aug 19, 2019

China SXT Pharmaceuticals, Inc. Announces Filing of Annual Report on Form 20-F for Year Ended March 31, 2019

Aug 12, 2019

China SXT Pharmaceuticals, Inc. Receives New Pharmaceutical GMP Certificate

Jul 03, 2019

China SXT Pharmaceuticals, Inc. Announces TCM Homologous Supplements Production

May 22, 2019

China SXT Pharmaceuticals, Inc. Being Admitted to Hi-tech Zone of Huangshan City in Anhui Province

Apr 17, 2019

China SXT Pharmaceuticals, Inc. Announces Pricing of a $15 Million PIPE Financing

Apr 02, 2019

China SXT Pharmaceuticals, Inc. Receives National High-tech Enterprise Qualification

Mar 28, 2019

China SXT Pharmaceuticals, Inc. Announces Financial Results for the Six Months Ended September 30, 2018

Jan 02, 2019

China SXT Pharmaceuticals, Inc. Announces First Closing of Initial Public Offering

Sep 28, 2018

China SXT Pharmaceuticals, Inc. Announces Effectiveness of Registration Statement on Form F-1 and Pricing the Initial Public Offering of its Ordinary Shares at $4.00 per Share